Aurobindo Pharma Latest News

Q4 FY25 Financials and Performance Drivers: Aurobindo Pharma reported a solid Q4 FY25, with revenue climbing 10.6% year-on-year to ₹8,382 crore. This growth was primarily fueled by strong sales in its key US and European formulations markets, which grew by 13.5% and 17.2% respectively. While net profit saw a marginal dip to ₹903 crore, largely due to higher interest costs and depreciation, the company achieved a healthy EBITDA margin of 21.4%, indicating strong operational efficiency. For the full fiscal year, total revenue reached ₹31,724 crore with a 10% increase in profit. Key USFDA Approvals and Product Launches: Aurobindo Pharma continues to expand its product offerings in the US market. The company recently secured final USFDA approval for Dasatinib Tablets (generic Sprycel), a leukemia drug with an estimated US market size of $1.8 billion, with a launch planned for Q1 FY26. Additionally, it received final approval for Rivaroxaban 2.5mg tablets (generic Xarelto), targeting a $447 million market, and tentative approvals for higher strengths of Rivaroxaban, further strengthening its US generics pipeline. Strategic Expansion and Future Outlook: The company is strategically focused on volume-led growth and a diversified product portfolio, with ongoing investments in R&D and capacity enhancements, including its Penicillin G (PEN-G) project. Aurobindo Pharma's European operations are also nearing a significant $1 billion revenue milestone. Despite some analyst caution on short-term profit fluctuations, the company's continuous regulatory successes and strategic expansions position it for sustained long-term growth in the global pharmaceutical market.